Sign in →

Test Code BPAB Bullous Pemphigoid, BP180 and BP230, IgG Antibodies, Serum


Specimen Required


Collection Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Submission container/tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Useful For

Initial screening test in the diagnosis of bullous pemphigoid and its variants

 

Complementing the standard serum test of indirect immunofluorescence utilizing primate esophagus substrate and primate salt-split skin substrate (CIFS / Cutaneous Immunofluorescence Antibodies [IgG], Serum)

Reporting Name

BP 180 and 230, Serum

Specimen Type

Serum Red

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Red Refrigerated (preferred) 14 days
  Frozen  30 days
  Ambient  14 days

Reject Due To

Gross hemolysis OK
Gross lipemia OK
Gross icterus OK

Reference Values

BULLOUS PEMPHIGOID 180:

<20 RU/mL (negative)

≥20 RU/mL (positive)

 

BULLOUS PEMPHIGOID 230:

<20 RU/mL (negative)

≥20 RU/mL (positive)

Supportive Data

Thirty-two classic bullous pemphigoid (BP), 15 mucous membrane pemphigoid, and 7 other pemphigoid variants, diagnosed by direct immunofluorescence, routine histology, and clinical presentation were tested. Controls included 47 patients with other autoimmune blistering disorders and 42 age-matched controls without skin disease. Forty of 54 (74%) patients with BP and variants tested positive for BP180 and/or BP230 autoantibodies. Of these patients, 28 of 32 (88%) with classical BP, 8 of 15 (53%) with mucous membrane predominant (MMP), and 4 of 7 (57%) of other pemphigoid variants, tested positive.

 

The calculated sensitivities in classical BP were 54% for BP180 alone and 56% for BP230 alone. The sensitivity increased to 88% with both tests combined, which is comparable to that of indirect immunofluorescence (IIF) (88%). In MMP the calculated sensitivities were 47% for BP180 alone, 13% for BP230 alone, and 53% for both combined. This was slightly less than the sensitivity of IIF (67%). Only 5 of 47 (11%) and 2 of 47 (4%) control patients with other autoimmune blistering disorders were positive for BP180 and BP230 autoantibodies respectively. Interestingly, the 2 patients positive for BP230 autoantibody had paraneoplastic pemphigus. One of 42 (2%) and 0 normal controls tested positive for BP180 and BP230 respectively.

 

The calculated specificities for BP180, BP230, and IIF were 93%, 98%, and 92% respectively.

Day(s) Performed

Varies

Report Available

1 to 5 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT Code Information

83516 x 2

LOINC Code Information

Test ID Test Order Name Order LOINC Value
BPAB BP 180 and 230, Serum 92671-7

 

Result ID Test Result Name Result LOINC Value
606816 BP 180, S 53842-1
606817 BP 230, S 53843-9

Specimen Retention Time

30 days